...
首页> 外文期刊>Life Science Journal >Characterization of recombinant protein of Pasteurella multocida serotype B
【24h】

Characterization of recombinant protein of Pasteurella multocida serotype B

机译:多杀性巴斯德氏菌血清型B重组蛋白的表征

获取原文
           

摘要

Haemorrhagic septicaemia (HS) is an acute, fatal septicaemic bacterial disease, mainly in South and Southeast Asia, Africa and India which caused by Pasteurella multocida, a gram negative coccobacilli bacterium. The effectiveness and safety of available treatment and vaccines are limited due to antimicrobial resistance. The objective of this study was to characterize recombinant protein of Pasteurella multocida in developing vaccine against HS. Results: Bacterial culture strain was cultured in brain heart infusion (BHI) medium. Soluble proteins were extracted and separated electrophoretically using 12% gradient sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Immunogenic soluble proteins were detected by western blotting using anti-Pasteurella serum raised in rabbit against whole cell antigens of Pasteurella multocida and anti-rabbit antibody and identified. Recombinant protein was then expressed and transformed in E.coli. Expression and purification of recombinant protein was analyzed using SDS-Page. The separation of soluble proteins showed various molecular weights on the gel, ranging from 10kDA to 170kDA. According to the western blot analysis, the most intense band detected was of approximately 28kDA and identified as lipoprotein B. Immunogenicity study of soluble protein will be carried out in response to immunogenic roles against HS and potential role in vaccine development. Purified recombinant protein size was obtained approximately 39kDa after electropherically separated using 12% SDS-Page. Conclusion: According to the immunoblotting analysis, intensity band of purified recombinant protein treated with antisera from immunized rabbit detected on film was 5398.78 with p-value equal to 0.0006 (p-value P.multocida was characterized and indicated. Further study on the immunogenicity study of recombinant protein will be carried out in response to immunogenic roles against HS and potential role in vaccine development.
机译:出血性败血病(HS)是一种急性致命性败血性细菌性疾病,主要发生在南亚,东南亚,非洲和印度,由革兰氏阴性球菌巴斯德氏菌引起。可用的治疗方法和疫苗的有效性和安全性由于抗微生物性而受到限制。这项研究的目的是在研发抗HS疫苗时鉴定多杀巴斯德氏菌的重组蛋白。结果:细菌培养菌株在脑心浸液(BHI)培养基中培养。提取可溶性蛋白,并使用12%梯度十二烷基硫酸钠聚丙烯酰胺凝胶电泳(SDS-PAGE)进行电泳分离。使用兔抗多杀巴斯德氏菌全细胞抗原的抗巴氏杆菌血清和抗兔抗体,通过蛋白质印迹法检测免疫原性可溶性蛋白并进行鉴定。然后表达重组蛋白并在大肠杆菌中转化。使用SDS-Page分析重组蛋白的表达和纯化。可溶性蛋白质的分离在凝胶上显示出各种分子量,范围从10kDA到170kDA。根据蛋白质印迹分析,检测到的最强条带约为28kDA,被鉴定为脂蛋白B。可溶性蛋白的免疫原性研究将针对针对HS的免疫原性作用和疫苗开发中的潜在作用进行。使用12%SDS-Page电分离后,大约39kDa可获得纯化的重组蛋白大小。结论:根据免疫印迹分析,在膜上检测到的经免疫兔抗血清纯化的重组蛋白的强度谱带为5398.78,p值等于0.0006(表征并表明了p值多杀梭状芽孢杆菌。进一步的免疫原性研究响应于针对HS的免疫原性作用和在疫苗开发中的潜在作用,将进行重组蛋白的制备。

著录项

  • 来源
    《Life Science Journal》 |2014年第12期|共7页
  • 作者

  • 作者单位
  • 收录信息
  • 原文格式 PDF
  • 正文语种
  • 中图分类 药学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号